Search research articles
Contact Us
Filters
Showing results (41-50 of 260) with videos related to
Page
of 26
Sort By:
Current Opinion in Pharmacology
|
June 29, 2015
Drugging PI3K in cancer: refining targets and therapeutic strategies
Timothy A Yap, Lynn Bjerke, Paul A Clarke, et al.
Cancer Discovery
|
June 4, 2017
Targeting <i>BRAF</i>-Mutant Colorectal Cancer: Progress in Combination Strategies
Raghav Sundar, David S Hong, Scott Kopetz, et al.
Cancer Biology & Medicine
|
July 27, 2016
Immuno-oncology combinations: raising the tail of the survival curve
Samuel J Harris, Jessica Brown, Juanita Lopez, et al.
Cancer Discovery
|
July 3, 2016
CDK4/6 Inhibitors: Promising Opportunities beyond Breast Cancer
Joline S J Lim, Nicholas C Turner, Timothy A Yap
Chinese Journal of Cancer
|
May 7, 2013
Targeting the PI3K-AKT-mTOR signaling network in cancer
Khurum H Khan, Timothy A Yap, Li Yan, et al.
British Journal of Cancer
|
December 17, 2020
The role of Schlafen 11 (SLFN11) as a predictive biomarker for targeting the DNA damage response
Niamh Coleman, Bingnan Zhang, Lauren A Byers, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 13, 2016
Combining Molecularly Targeted Agents: Is More Always Better?
Raghav Sundar, Nicola Valeri, Kevin J Harrington, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting
|
May 18, 2019
The DNA Damaging Revolution: PARP Inhibitors and Beyond
Timothy A Yap, Ruth Plummer, Nilofer S Azad, et al.
Current Problems in Cancer
|
July 1, 2017
Targeting ATR in cancer medicine
Raghav Sundar, Jessica Brown, Alvaro Ingles Russo, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting
|
May 28, 2026
Novel Synthetic Lethal Therapeutic Strategies in Precision Oncology
Timothy A Yap, Fiona Simpkins, Marie Porte, et al.
Page
of 26
Search research articles
Search
Showing results (41-50 of 260) with videos related to
Sort By:
Page
of 26
Current Opinion in Pharmacology
|
June 29, 2015
Drugging PI3K in cancer: refining targets and therapeutic strategies
Timothy A Yap, Lynn Bjerke, Paul A Clarke, et al.
Cancer Discovery
|
June 4, 2017
Targeting <i>BRAF</i>-Mutant Colorectal Cancer: Progress in Combination Strategies
Raghav Sundar, David S Hong, Scott Kopetz, et al.
Cancer Biology & Medicine
|
July 27, 2016
Immuno-oncology combinations: raising the tail of the survival curve
Samuel J Harris, Jessica Brown, Juanita Lopez, et al.
Cancer Discovery
|
July 3, 2016
CDK4/6 Inhibitors: Promising Opportunities beyond Breast Cancer
Joline S J Lim, Nicholas C Turner, Timothy A Yap
Chinese Journal of Cancer
|
May 7, 2013
Targeting the PI3K-AKT-mTOR signaling network in cancer
Khurum H Khan, Timothy A Yap, Li Yan, et al.
British Journal of Cancer
|
December 17, 2020
The role of Schlafen 11 (SLFN11) as a predictive biomarker for targeting the DNA damage response
Niamh Coleman, Bingnan Zhang, Lauren A Byers, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 13, 2016
Combining Molecularly Targeted Agents: Is More Always Better?
Raghav Sundar, Nicola Valeri, Kevin J Harrington, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting
|
May 18, 2019
The DNA Damaging Revolution: PARP Inhibitors and Beyond
Timothy A Yap, Ruth Plummer, Nilofer S Azad, et al.
Current Problems in Cancer
|
July 1, 2017
Targeting ATR in cancer medicine
Raghav Sundar, Jessica Brown, Alvaro Ingles Russo, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting
|
May 28, 2026
Novel Synthetic Lethal Therapeutic Strategies in Precision Oncology
Timothy A Yap, Fiona Simpkins, Marie Porte, et al.
Page
of 26